ADMINISTRATION The Core is administered jointly by Drs. J. Rivier, B. Olivera, M. Mclntosh and W. Fischer. Priorities will be assigned in consultation with the users as defined in the application. In general, a first come, first served policy will be used to assign priority. The Advisory Committee consists of all of the Project Leaders of this Program (including the Core Directors). The Advisory Committee meets on a scheduled basis once a year, and will meet on an ad hoc basis as needed, in order to address new developments in the operation of the Core as well as to resolve conflicts, or to set priorities other than those derived from records of first come, first served. The services provided by this Core have been provided to the Program in a timely and responsive manner since its inception. We request support for only one-fourth of the personnel and costs associated with the optimal functioning of this Core, because of our similar commitments to other NIH agencies. Accurate and complete documentation of peptide synthesis and analyses will be kept, using computer storage methods where possible. Similarly, Core B will keep the bulk of the material synthesized under its aegis for accurate accounting, proper storage and distribution (with the applicable Project Leader's authorization) to other NIH sponsored researchers after publication of the results derived from the use of these peptides. NOTES: This Core will operate in the laboratories of the P.I. (J. Rivier). Laboratory space has been recently renovated and designated specifically to fulfill the needs of the CDC for the synthesis and storage of select agents. The Facility is now registered with the CDC (see attached Certificate of Registration) to carry out the proposed research, including the synthesis of conotoxins, their purification, storage and the ability to transfer them to researchers under the conditions specified in the Salk's registration application. The Salk's registration application is available upon request.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Program Projects (P01)
Project #
5P01GM048677-18
Application #
8145713
Study Section
Special Emphasis Panel (ZRG1)
Project Start
Project End
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
18
Fiscal Year
2010
Total Cost
$179,183
Indirect Cost
Name
University of Utah
Department
Type
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Yan, Yijin; Peng, Can; Arvin, Matthew C et al. (2018) Nicotinic Cholinergic Receptors in VTA Glutamate Neurons Modulate Excitatory Transmission. Cell Rep 23:2236-2244
Hone, Arik J; McIntosh, J Michael (2018) Nicotinic acetylcholine receptors in neuropathic and inflammatory pain. FEBS Lett 592:1045-1062
Hone, Arik J; Talley, Todd T; Bobango, Janet et al. (2018) Molecular determinants of ?-conotoxin potency for inhibition of human and rat ?6?4 nicotinic acetylcholine receptors. J Biol Chem 293:17838-17852
Banala, Sambashiva; Arvin, Matthew C; Bannon, Nicholas M et al. (2018) Photoactivatable drugs for nicotinic optopharmacology. Nat Methods 15:347-350
Hone, Arik J; Servent, Denis; McIntosh, J Michael (2018) ?9-containing nicotinic acetylcholine receptors and the modulation of pain. Br J Pharmacol 175:1915-1927
Espino, Samuel S; Robinson, Samuel D; Safavi-Hemami, Helena et al. (2018) Conopeptides promote itch through human itch receptor hMgprX1. Toxicon 154:28-34
Richter, Katrin; Sagawe, Sabrina; Hecker, Andreas et al. (2018) C-Reactive Protein Stimulates Nicotinic Acetylcholine Receptors to Control ATP-Mediated Monocytic Inflammasome Activation. Front Immunol 9:1604
Hiller, Sebastian Daniel; Heldmann, Sarah; Richter, Katrin et al. (2018) ?-Nicotinamide Adenine Dinucleotide (?-NAD) Inhibits ATP-Dependent IL-1? Release from Human Monocytic Cells. Int J Mol Sci 19:
Peng, Can; Yan, Yijin; Kim, Veronica J et al. (2018) Gene editing vectors for studying nicotinic acetylcholine receptors in cholinergic transmission. Eur J Neurosci :
Chen, De-Jie; Gao, Fen-Fei; Ma, Xiao-Kuang et al. (2018) Pharmacological and functional comparisons of ?6/?3?2?3-nAChRs and ?4?2-nAChRs heterologously expressed in the human epithelial SH-EP1 cell line. Acta Pharmacol Sin 39:1571-1581

Showing the most recent 10 out of 277 publications